Corvia Medical, Inc.
Privately held medical device company headquartered in Tewksbury, MA focused on development, clinical evaluation, regulatory approval, and commercialization of a transcatheter interatrial shunt implant intended to reduce left atrial pressure and treat heart failure with preserved or mildly reduced ejection fraction. The company has led multi-center randomized, sham-controlled clinical programs, published long-term outcome and imaging data, and pursued regulatory clearances including CE certification in the EU and FDA Breakthrough Device designation.
Industries
N/A
Products
Interatrial shunt implant (transcatheter)
A catheter-delivered implant that creates a controlled passage between the left and right atria to reduce elevated left atrial pressure in patients with heart failure with preserved or mildly reduced ejection fraction.
Interatrial shunt implant (transcatheter)
A catheter-delivered implant that creates a controlled passage between the left and right atria to reduce elevated left atrial pressure in patients with heart failure with preserved or mildly reduced ejection fraction.
Expertise Areas
- Transcatheter structural heart device development
- Clinical trial design and execution (randomized, sham-controlled)
- Heart failure therapeutics (HFpEF/HFmrEF)
- Regulatory strategy and submissions (FDA, EU MDR)
Key Technologies
- Transcatheter implantable interatrial shunt
- Catheter-based percutaneous implantation
- Invasive exercise hemodynamic testing
- Echocardiographic serial imaging